Hus M - Search Results

1

Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma.

Hus M, Grzasko N, Szostek M, Pluta A, Helbig G, Woszczyk D, Adamczyk-Cioch M, Jawniak D, Legiec W, Morawska M, Kozinska J, Waciński P, Dmoszynska A. Hus M, et al. Ann Hematol. 2011 Oct;90(10):1161-6. doi: 10.1007/s00277-011-1276-2. Epub 2011 Jun 23. Ann Hematol. 2011. PMID: 21698395 Free PMC article. Clinical Trial.

2

Low dose cytosine arabinoside in the treatment of the primary myelodysplastic syndrome.

Pluta A, Kowalewski J, Kurowska M, Spiewak H, Hus M. Pluta A, et al. Among authors: hus m. Folia Haematol Int Mag Klin Morphol Blutforsch. 1990;117(6):787-91. Folia Haematol Int Mag Klin Morphol Blutforsch. 1990. PMID: 1713883

3

[Clinical and immunologic characteristics of CD 34 positive acute myeloid leukemia].

Adamczyk-Cioch MB, Dmoszyńska A, Hus M, Hus I. Adamczyk-Cioch MB, et al. Among authors: hus m, hus i. Pol Arch Med Wewn. 1995 Jul;94(1):40-6. Pol Arch Med Wewn. 1995. PMID: 8524698 Polish.

4

Interferon production by peripheral blood leukocytes of patients with acute myeloid leukemia.

Kandefer-Szerszeń M, Dmoszyńska A, Borowska L, Adamczyk-Cioch M, Hus M, Hus I, Roliński J. Kandefer-Szerszeń M, et al. Among authors: hus m, hus i. Arch Immunol Ther Exp (Warsz). 1996;44(2-3):119-22. Arch Immunol Ther Exp (Warsz). 1996. PMID: 8915515

5

Thalidomide treatment of resistant or relapsed multiple myeloma patients.

Hus M, Dmoszynska A, Soroka-Wojtaszko M, Jawniak D, Legiec W, Ciepnuch H, Hellmann A, Wolska-Smolen T, Skotnicki A, Manko J; Polish Multiple Myeloma Study Group. Hus M, et al. Haematologica. 2001 Apr;86(4):404-8. Haematologica. 2001. PMID: 11325647 Clinical Trial.

6

[Evaluation of blood morphology in patients with refractory multiple myeloma treated with thalidomide].

Grzaśko N, Dmoszyńska A, Krawczyk S, Hus M, Soroka-Wojtaszko M, Ciepłuch H, Hellmann A. Grzaśko N, et al. Among authors: hus m. Pol Arch Med Wewn. 2001 Jul;106(1):573-9. Pol Arch Med Wewn. 2001. PMID: 11928568 Polish.

7

Influence of thalidomide on Bcl2 expression and proangiogenic cytokine levels in short-term culture of peripheral blood and bone marrow mononuclear cells of multiple myeloma patients.

Dmoszyńska A, Roliński J, Bojarska-Junak A, Mańko J, Jawniak D, Walter-Croneck A, Soroka-Wojtaszko M, Hus M. Dmoszyńska A, et al. Among authors: hus m. Pol J Pharmacol. 2001 Nov-Dec;53(6):709-13. Pol J Pharmacol. 2001. PMID: 11985351 Free article.

8

Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma.

Dmoszyńska A, Bojarska-Junak A, Domański D, Roliński J, Hus M, Soroka-Wojtaszko M. Dmoszyńska A, et al. Among authors: hus m. Leuk Lymphoma. 2002 Feb;43(2):401-6. doi: 10.1080/10428190290006224. Leuk Lymphoma. 2002. PMID: 11999576

9

An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma.

Hus I, Dmoszynska A, Manko J, Hus M, Jawniak D, Soroka-Wojtaszko M, Hellmann A, Ciepluch H, Skotnicki A, Wolska-Smolen T, Sulek K, Robak T, Konopka L, Kloczko J. Hus I, et al. Among authors: hus m. Br J Cancer. 2004 Nov 29;91(11):1873-9. doi: 10.1038/sj.bjc.6602225. Br J Cancer. 2004. PMID: 15520820 Free PMC article.

10

Long-term thalidomide therapy resulted in lack of mdr1 gene expression in a patient with primary resistant multiple myeloma.

Hus M, Dmoszyńska A, Kocki J, Hus I, Jawniak D, Adamczyk-Cioch M, Grzasko N. Hus M, et al. Among authors: hus i. Leukemia. 2005 Aug;19(8):1497-9. doi: 10.1038/sj.leu.2403811. Leukemia. 2005. PMID: 15920492 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

141 results

Search Page

Filters